Swanton Charles, Szallasi Zoltan, Brenton James D, Downward Julian
Translational Cancer Therapeutics Laboratory, Cancer Research UK London Research Institute, London, UK.
Breast Cancer Res. 2008;10(5):214. doi: 10.1186/bcr2159. Epub 2008 Oct 31.
The widespread introduction of high throughput RNA interference screening technology has revealed tumour drug sensitivity pathways to common cytotoxics such as paclitaxel, doxorubicin and 5-fluorouracil, targeted agents such as trastuzumab and inhibitors of AKT and Poly(ADP-ribose) polymerase (PARP) as well as endocrine therapies such as tamoxifen. Given the limited power of microarray signatures to predict therapeutic response in associative studies of small clinical trial cohorts, the use of functional genomic data combined with expression or sequence analysis of genes and microRNAs implicated in drug response in human tumours may provide a more robust method to guide adjuvant treatment strategies in breast cancer that are transferable across different expression platforms and patient cohorts.
高通量RNA干扰筛选技术的广泛应用，揭示了肿瘤对常见细胞毒性药物（如紫杉醇、阿霉素和5-氟尿嘧啶）、靶向药物（如曲妥珠单抗以及AKT和聚（ADP-核糖）聚合酶（PARP）抑制剂）以及内分泌治疗药物（如他莫昔芬）的药物敏感性途径。鉴于在小型临床试验队列的相关性研究中，微阵列特征预测治疗反应的能力有限，结合人类肿瘤中与药物反应相关的基因和微小RNA的表达或序列分析的功能基因组数据的使用，可能提供一种更可靠的方法来指导乳腺癌的辅助治疗策略，该策略可在不同的表达平台和患者队列中通用。
